Revenue of approximately $34.9 million for the three months ended December 31, 2024, representing 11% year-over-year growth.
Instruments revenue of approximately $3.1 million, representing a 6% year-over-year decline.
Consumables revenue of approximately $17.4 million, remaining flat year-over-year.
Accelerator revenue of approximately $8.6 million, representing 22% year-over-year growth. As previously disclosed, the fourth quarter performance does not include $1.5 million of revenue from an order under an agreement with Eli Lilly, which was completed in the third quarter of 2024.
Other revenue of approximately $5.8 million, representing 57% year-over-year growth.
The Company used approximately $4.4 million of cash in the quarter ended December 31, 2024.